Headline » News
Yesterday was the final day of this year’s American Society of Hematology (ASH) meeting, which took place in New Orleans.
Sessions throughout the day on Monday and yesterday featured a wide range of interesting presentations about myelodysplastic syndromes (MDS).
For example, initial results of a Phase 2 study of Zolinza (vorinostat) in combination with Vidaza (azacitidine) show that three-quarters of patients responded to the treatment combination and the median overall survival was 27.6 months, which is greater than what has been observed with Vidaza alone.
Another study showed that the revised International Prognostic Scoring System (IPSS-R) is not only useful for determining prognosis at the time of diagnosis but also at the time of transplantation.
A third study highlighted the features of MDS patients with …Read the full story »
Articles written by patients and caregivers about their experiences living with MDS.